Ginkgo Bioworks Holdings (DNA) Other Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Other Non-Current Assets of $3.2 million for Q1 2026, down 93.14% year-on-year from $46.8 million in Q1 2025, and down 93.19% on a QoQ basis from $47.2 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Other Non-Current Assets data on file, last reported at $3.2 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 93.14% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (down 93.14% YoY), and the FY2025 full-year result was $47.2 million, down 14.76% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.2 million, down from $47.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $97.9 million in Q2 2023 and bottomed at $3.2 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $55.3 million (2024), against an average of $59.5 million.
- The widest annual swing landed in 2023, when Other Non-Current Assets soared 120.87%; it then sank 93.14% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $88.7 million in 2022, then plunged by 34.57% to $58.1 million in 2023, then decreased by 4.68% to $55.3 million in 2024, then slipped by 14.76% to $47.2 million in 2025, then sank by 93.19% to $3.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $3.2 million (Q1 2026), $47.2 million (Q4 2025), and $46.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | 3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 47.17 Mn |
| Sep 30, 2025 | 46.59 Mn |
| Jun 30, 2025 | 47.02 Mn |
| Mar 31, 2025 | 46.78 Mn |
| Dec 31, 2024 | 55.34 Mn |
| Sep 30, 2024 | 59.79 Mn |
| Jun 30, 2024 | 60.21 Mn |
| Mar 31, 2024 | 60.63 Mn |
| Dec 31, 2023 | 58.06 Mn |
| Sep 30, 2023 | 97.02 Mn |
| Jun 30, 2023 | 97.95 Mn |
| Mar 31, 2023 | 97.26 Mn |
| Dec 31, 2022 | 88.73 Mn |
| Sep 30, 2022 | 43.93 Mn |
| Jun 30, 2022 | 53.02 Mn |
| Mar 31, 2022 | 49.62 Mn |
| Dec 31, 2021 | 43.99 Mn |
| Sep 30, 2021 | 26.80 Mn |
| Dec 31, 2020 | 5.60 Mn |